Innate Pharma S.A.
Innate Pharma S.A. (IPHA) Revenue
Annual & quarterly revenue history · segment & region breakdown
IPHA · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsInnate Pharma S.A. trailing twelve-month (TTM) revenue is $0.02B, a decrease of 77.92% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.01B | -77.92% |
| 2024-12-31 | $0.01B | -$0.04B | -75.68% |
| 2023-12-31 | $0.05B | -$0.01B | -10.01% |
| 2022-12-31 | $0.06B | +$0.05B | +376.17% |
| 2021-12-31 | $0.01B | -$0.06B | -82.64% |
| 2020-12-31 | $0.07B | +$0.00B | +1.16% |
| 2019-12-31 | $0.07B | -$0.01B | -13.67% |
| 2018-12-31 | $0.08B | +$0.05B | +144.83% |
| 2017-12-31 | $0.03B | -$0.02B | -41.90% |
| 2016-12-31 | $0.06B | +$0.04B | +213.64% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Innate Pharma S.A. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Innate Pharma S.A. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in EUR.
Data sourced from Innate Pharma S.A.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IPHA revenue · 4 questionsIPHA's trailing twelve-month (TTM) revenue is $0.02B. That is a decrease of 77.92% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Innate Pharma S.A. SEC filings · GAAP · Innate Pharma S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026